BioAngels makes first local investment
27 November, 2003 by Melissa TrudingerMembers of South Australia's BioAngels have made their first investment into the South Australian bioscience sector, selecting Australian Orthopaedic Innovations from more than 20 applications.
Rockeby Biomed readies for IPO
26 November, 2003 by Melissa TrudingerDiagnostics company Rockeby Biomed is readying itself to float on the ASX in a back door listing through Carbine Corporation.
pSvida acquisition opens diagnostic pathway
26 November, 2003 by Melissa TrudingerPerth-based nanomaterials specialist pSivida (ASX:PSD) has acquired the rights to use porous silicon mirror technology from German research agency Forschungszentrum Julich.
BresaGen sells its catheter technology
26 November, 2003 by Melissa TrudingerBresaGen (ASX:BGN) has assigned its cell delivery catheter licenses to North American company NexGen Technologies for about $380,000 plus a four per cent share in NexGen.
BioDiem readies for December IPO
25 November, 2003 by Melissa TrudingerMelbourne biotechnology company BioDiem has lodged a prospectus with ASIC for an AUD$10 million float opening on December 4.
Phenomix expands its Australian operations
25 November, 2003 by Melissa TrudingerPhenomix, based jointly in San Diego and Canberra, has appointed experienced biotechnology executive Dr Julie Cherrington as president of operations to oversee its Australian activities as it moves into pre-clinical and clinical programs.
Cochlear names new CEO
25 November, 2003 by Melissa TrudingerCochlear has named ResMed executive VP Dr Chris Roberts as its new CEO, replacing Jack O'Mahony.
Polartechnics raises $11.25m; plans global push
24 November, 2003 by Melissa TrudingerSydney-based medical device firm Polartechnics (ASX:PLT) has used a combination of a share placement and a share purchase plan to raise AUD$11.25 million to expand its global sales and marketing efforts and refine its production processes.
Solbec gets nod on cancer drug trial
24 November, 2003 by Melissa TrudingerPerth biotech Solbec Pharmaceuticals (ASX:SBP) has received approval to commence a Phase I clinical trial on its lead cancer therapeutic SBP002.
Vics pledge $1.5m to wallaby genome project
24 November, 2003 by Melissa TrudingerVictoria's state government has pledged AUD$1.5 million funding for a wallaby genome project, which needs around $6 million to match US National Institutes of Health funding to proceed.
Amrad boosted by US$3 million milestone payment
20 November, 2003 by Melissa TrudingerAmrad (ASX: AML) has received its first milestone payment from its exclusive licensing and research collaboration agreement with Merck, Sharp and Dohme (MSD).
AGT deal targets OTC obesity products
20 November, 2003 by Melissa TrudingerAGT Biosciences (ASX: AGT) has signed an agreement with US drug discovery company the Institutes for Pharmaceutical Discovery (IPD) to collaborate on the development of over-the-counter (OTC) drugs for obesity.
Norwood Releases Data on Immune-boosting Therapy
19 November, 2003 by Graeme O'NeillResearchers working with Melbourne medical technology company Norwood Abbey (ASX: NAL) will present results from their trials on the company's promising immune-boosting therapy in leukaemia and lymphoma patients at next month's meeting of the American Society of Haematology (ASH) in Washington, DC.
Novogen granted key phenoxodiol patent in US
19 November, 2003 by Graeme O'NeillSydney pharmaceutical company Novogen (ASX: NRT, NASDAQ: NVGN) has been granted a US patent covering all applications of its promising anti-cancer therapeutic phenoxodiol for benign and malignant cancers, including ovarian, breast, prostate and cervical cancers.
Agenix's D-dimer diagnostics get boost from international studies
19 November, 2003 by Graeme O'NeillTwo studies published recently in leading medical research journals have given ticks to the SimpliRED and Simplify blood-clot diagnostics developed by Brisbane biotech Agenix (ASX: AGX, NASDAQ: AGXLY)
